Aarti Pharma Labs Stock Screener | Share Price & Fundamental Analysis

Share Price NSE
₹705.75
▼ -17.95 (-2.48%)
2026-03-02 00:00:00
Share Price BSE
₹706.65
▼ -16.75 (-2.32%)
2026-03-02 00:00:00
Track Aarti Pharma Labs share price live with TickJournal's free stock screener. Analyze Aarti Pharma Labs share price history trends and compare 52-week high low levels. Calculate AARTIPHARM stock fair value using fundamental analysis and view live share price charts. Determine Aarti Pharma Labs share intrinsic value and compare it with current AARTIPHARM share price. Record your Aarti Pharma Labs trades in TickJournal's free trading journal and track your portfolio performance.
EPS (TTM) ₹30.06
Dividend Yield 0.70%
Debt to Equity 0.19
Aarti Pharma Labs 52 Week Low ₹624.40
Operating Margin 23.00%
Profit Margin 10.98%
EBITDA ₹104.00
Net Income ₹48.00
Total Assets ₹2,906.00
Total Equity ₹1,990.00

Aarti Pharma Labs Share Price History - Stock Screener Chart

Screen AARTIPHARM historical share price movements with interactive charts. Analyze price trends and patterns.

Aarti Pharma Labs Company Profile - Fundamental Screener

Screen Aarti Pharma Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AARTIPHARM shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE0LRU01027

Aarti Pharma Labs Balance Sheet Screener

Screen AARTIPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021
Assets
Total Assets 2,906 2,582 2,244 2,040 0
Current Assets 1,322 1,346 1,163 1,028 0
Fixed Assets 1,137 1,033 926 782 0
Liabilities
Total Liabilities 0 0 0 0 0
Current Liabilities 259 131 85 73 0
Non-Current Liabilities 0 0 0 0 0
Shareholders' Equity
Total Equity 1,990 1,757 1,559 1,387 0
Share Capital 45 45 45 0 0
Reserves & Surplus 1,945 1,712 1,513 1,341 0

Aarti Pharma Labs Income Statement Screener - Profit & Revenue Analysis

Screen Aarti Pharma Labs income statement and profit fundamentals. Analyze AARTIPHARM quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Aarti Pharma Labs share price evaluation.
Item 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec 2022-Sept 2022-Jun
Revenue 437 418 388 562 543 463 558 508 450 441 459 486 472 532 457
Expenses 333 344 293 418 409 364 459 388 353 352 374 405 385 441 371
EBITDA 104 74 95 144 134 98 99 120 97 89 85 81 87 91 86
Operating Profit % 23.00% 18.00% 24.00% 26.00% 24.00% 20.00% 17.00% 23.00% 21.00% 20.00% 19.00% 16.00% 18.00% 17.00% 19.00%
Depreciation 29 25 23 23 23 21 20 19 19 18 17 16 16 17 14
Interest 13 11 7 7 10 6 5 5 5 4 4 6 5 6 4
Profit Before Tax 63 39 65 115 101 72 74 96 74 67 64 59 65 69 68
Tax 15 11 16 26 27 17 18 31 21 15 17 16 17 18 16
Net Profit 48 28 50 88 74 55 56 65 53 52 47 43 48 51 52
EPS 5.29 3.08 5.46 9.75 8.16 6.03 6.12 7.20 5.82 5.72 5.20 4.73 5.26 5.64 5.72

Aarti Pharma Labs Cash Flow Screener - Liquidity Fundamentals

Screen AARTIPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March
Operating Activities 332 216 250 -44 0
Investing Activities -414 -215 -158 -139 0
Financing Activities 65 10 -164 260 0
Net Cash Flow -17 12 -71 78 0

Aarti Pharma Labs Shareholding Pattern Screener

See Aarti Pharma Labs shareholding pattern with promoter, FII, and DII holdings. Check Aarti Pharma Labs promoter holding and ownership changes for AARTIPHARM on TickJournal.
Item 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar
Promoter Holding 43.10% 42.88% 43.72% 44.29% 44.66% 46.10% 46.46% 46.46%
FII Holding 7.68% 8.02% 7.35% 7.36% 8.64% 7.38% 7.06% 8.32%
DII Holding 7.66% 6.96% 7.80% 7.53% 10.36% 11.35% 11.47% 9.97%
Govt Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
Public Holding 34.85% 35.39% 34.43% 34.10% 30.39% 29.45% 29.57% 29.71%
Other Holding 6.70% 6.74% 6.69% 6.71% 5.94% 5.71% 5.43% 5.52%
Shareholder Count 184,489 190,655 187,039 196,314 185,111 185,436 189,012 204,122

Aarti Pharma Labs Share Dividend Screener - Share Yield Analysis

Check Aarti Pharma Labs dividend history with payout and yield data. View Aarti Pharma Labs dividend details including ex-dates and amounts for AARTIPHARM stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹5.00 0.69%
2024-March ₹3.00 0.40%
2023-March ₹2.00 0.46%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Aarti Pharma Labs Stock Index Membership

See which indices include Aarti Pharma Labs stock. Check AARTIPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.

Aarti Pharma Labs Market Events Screener - Corporate Actions

Get Aarti Pharma Labs corporate actions including splits, bonuses, and buybacks. Check Aarti Pharma Labs stock events that may affect AARTIPHARM share price.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA 10.17%
Dividend ₹ 2.50 /share 21.02%
2026-02-16 2026-02-16 Dividend ₹ 1.50 /share -8.86%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 1.87%
2025-11-09 2025-11-09 Quarterly Result Announcement NA 3.80%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -5.82%
2025-05-10 2025-05-10 Quarterly Result Announcement NA 1.53%
2025-02-14 2025-02-14 Dividend ₹ 2.50 /share 18.21%
2025-02-05 2025-02-05 Quarterly Result Announcement NA 4.31%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -1.13%
2024-08-07 2024-08-07 Annual General Meeting NA -1.81%
2024-07-31 2024-07-31 Dividend ₹ 1.00 /share 21.96%
2024-02-16 2024-02-19 Dividend ₹ 2.00 /share -2.52%

Aarti Pharma Labs Competitors Screener - Peer Comparison

Screen AARTIPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 416,764 39.09 54,729 9.71% 10,980 55.50
Divis Laboratories 170,126 69.29 9,712 18.67% 2,191 57.58
Torrent Pharmaceuticals 146,659 65.55 11,539 6.99% 1,911 65.06
Cipla 108,904 24.19 28,410 7.12% 5,291 47.64
Dr Reddys Laboratories 107,359 19.93 33,741 16.73% 5,725 55.60
Lupin 105,151 22.74 22,910 13.74% 3,306 66.87
Mankind Pharma 92,782 52.20 12,744 20.90% 2,007 63.52
Zydus Life Science 92,745 18.78 23,511 18.55% 4,615 55.01
Aurobindo Pharma 70,881 20.37 32,346 9.43% 3,484 58.41
Alkem Laboratories 67,429 28.38 13,458 3.70% 2,216 51.36

Aarti Pharma Labs Company Announcements - News Screener

Screen AARTIPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-02-16 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View
2026-02-13 Clarification Regarding Delay In Disclosure Of Event To The Exchange View
2026-02-11 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2026-02-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome View
2026-02-10 Corrigendum To Intimation Of Record Date For Dividend Dated February 09 2026. View
2026-02-10 Announcement under Regulation 30 (LODR)-Investor Presentation View
2026-02-09 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS View
2026-02-09 Fixation Of Record Date For Interim Dividend View
2026-02-09 Corporate Action-Board approves Dividend View
2026-02-09 Financial Results For The Quarter And Nine Months Ended December 31 2025 View
2026-02-09 Board Meeting Outcome for Outcome Of Board Meeting Held On February 9 2026 View
2026-02-06 Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 View
2026-02-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation View
2026-01-29 Board Meeting Intimation for 1. Board Meeting Intimation For Unaudited Financial Results Of The Company For The Quarter And Nine-Months Ended December 31 2025 2. Declaration Of Interim Dividend If Any On The Equity Share Capital Of The Company For The Fi View
2026-01-12 Clarification With Respect To Increase In Volume View
2026-01-12 Clarification sought from Aarti Pharmalabs Ltd -
2026-01-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View
2026-01-01 Announcement under Regulation 30 (LODR)-Change in Management View
2025-12-22 Closure of Trading Window View
2025-11-17 Announcement under Regulation 30 (LODR)-Earnings Call Transcript View